BMS bets on a decades-old drug, Cobenfy, to tackle Alzheimer's psychosis

Bristol Myers Squibb bets that Cobenfy, a 30-year-old drug, can become the first approved treatment for psychosis in Alzheimer's disease; its fate hinges on three pivotal trials later this year after a long-ago trial showed promise but was marred by adverse effects, a rescue journey from Eli Lilly to Karuna Therapeutics before landing with BMS.